Cryoprecipitate or Concentrate: Replacing Fibrinogen in a Postpartum Hemorrhage
A new mother's fibrinogen has collapsed well below her own pregnancy baseline during ongoing postpartum hemorrhage — and the team disagrees over whether the faster-reconstituting, off-label product or the slower, on-label one should go in first.
Whitney T., a 29-year-old woman, married three years ago on a rain-soaked Saturday she still describes as the best day of her life, delivered her first child vaginally six hours ago after an otherwise unremarkable pregnancy and labor. Uterine atony developed shortly after delivery of the placenta, and despite uterotonic medication and bimanual massage, her bleeding has continued; her estimated blood loss now exceeds 1,800 mL and climbing. Tranexamic acid was given within the first hour of the bleed being recognized, consistent with the WOMAN trial's own finding that early antifibrinolytic treatment reduces death from bleeding in postpartum hemorrhage, but it has not been enough on its own to slow her losses. A fibrinogen level sent forty minutes ago returned at 130 mg/dL — strikingly low not against a normal, non-pregnant reference range but against her own expected pregnancy baseline, which typically runs closer to 400-600 mg/dL by term. That gap is the actual signal: a level that would look unremarkable in a non-pregnant patient represents a real, substantial consumptive and dilutional coagulopathy in her, one now measurably contributing to the ongoing hemorrhage rather than merely accompanying it, and one her platelet count and prothrombin time — both still within normal limits — have not yet caught up to reflecting.
What the obstetric literature cannot tell her team is which product to reach for, because no completed randomized trial has ever compared cryoprecipitate against fibrinogen concentrate in postpartum hemorrhage. The two obstetric randomized trials that exist both tested concentrate against placebo, not against cryoprecipitate: FIB-PPH, which gave concentrate pre-emptively to women whose fibrinogen was still normal and found no benefit, and Collins and colleagues' OBS2, which randomized concentrate against placebo under viscoelastometric guidance and returned an adjusted incidence rate ratio of 0.72 for allogeneic units transfused, with a confidence interval from 0.3 to 1.7 and a p-value of 0.45 — a result that did not reach significance and that its authors read as an argument against replacing fibrinogen while the level is still adequate. Neither describes Whitney, whose level is already 130 and still falling. The only randomized head-to-head data comparing the two products come from outside obstetrics entirely — FEISTY, in trauma, where Winearls and colleagues found both products raised fibrinogen but concentrate reached the patient faster, and FIBRES, in cardiac surgery, where concentrate was non-inferior to cryoprecipitate for acquired hypofibrinogenemia. Fibrinogen concentrate's FDA approval, meanwhile, covers congenital afibrinogenemia and hypofibrinogenemia, not the acquired, consumption-driven deficit Whitney is having today — a real gap between the population the drug was labeled for and the population actually standing to benefit from it in an American delivery suite this afternoon.
In the delivery suite, actively hemorrhaging
Use cryoprecipitate. It's what our blood bank actually stocks and has decades of practical experience with in postpartum hemorrhage, and fibrinogen concentrate's FDA approval covers congenital fibrinogen deficiency — a level she was born with, not the acquired drop she's having today from consumption and dilution. Reaching for an off-label product when a labeled, effective alternative is already thawing in our own inventory adds a documentation and consent complication we don't need in the middle of an active hemorrhage.
The label distinguishes congenital from acquired deficiency, but the drug doesn't — it raises fibrinogen the same way regardless of why her level is low.
Off-label doesn't mean unstudied — though I'll be honest that it isn't studied here. Nobody has randomized these two products against each other in a bleeding obstetric patient. What we have is FEISTY, where Winearls and colleagues randomized concentrate against cryoprecipitate in trauma and found both raised fibrinogen while concentrate got into the patient faster, and FIBRES, where concentrate was non-inferior to cryoprecipitate for acquired hypofibrinogenemia in cardiac surgery. Those are the wrong patients and I know it. But the mechanism I'm relying on is reconstitution time, and there is no reason a delivery suite should be the one place a thawing step stops mattering. She is actively bleeding right now — the fifteen to thirty minutes cryoprecipitate needs before it's even in the room is not a detail we can treat as incidental.
You're right that the label was written for a different population than the one in front of us — but I don't think that's actually the deciding fact today. Either product raises her fibrinogen level, and her fibrinogen level, not which manufacturer produced the rise, is what Collins's OBS2 protocol actually treated as the trigger for reassessment and further action.
Whichever product gets here faster, give it, recheck her level after that dose, and escalate the same way either drug would allow. OBS2 didn't establish that concentrate helps — its transfusion result missed significance outright. What its protocol did establish is the discipline of measuring, treating, and re-measuring on a clock, and that discipline is product-agnostic. Whichever bag reaches this room first is the right one.
Agreed within minutes: give the cryoprecipitate already thawing in the blood bank as soon as it arrives, since it had a head start by the time the discussion concluded, and hold fibrinogen concentrate in reserve for a second dose if her repeat level after the first units doesn't clear a set target. Her fibrinogen, rechecked forty minutes after the cryoprecipitate infused, rose from 130 mg/dL to 210 mg/dL, and her bleeding slowed enough over the following hour that a second dose wasn't needed.
Not agreed: whether this hospital's own default product should change going forward given the logistics argument raised today. The hematologist would still prefer fibrinogen concentrate stocked and used first-line for exactly the reconstitution-speed reason raised at the bedside; the transfusion medicine physician isn't persuaded an off-label product should become this center's default over one with a matching approved indication, absent stronger comparative outcome data than a feasibility trial provides. The question of which product this hospital's massive-hemorrhage protocol should name first was referred to the blood bank's own practice committee rather than settled today.